NASDAQ:ATRA

Atara Biotherapeutics Stock Forecast, Price & News

$12.75
-0.30 (-2.30 %)
(As of 07/30/2021 12:00 AM ET)
Add
Compare
Today's Range
$12.69
$13.05
50-Day Range
$12.59
$16.58
52-Week Range
$11.33
$28.20
Volume592,016 shs
Average Volume600,603 shs
Market Capitalization$1.07 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.45
30 days | 90 days | 365 days | Advanced Chart
Receive ATRA News and Ratings via Email

Sign-up to receive the latest news and ratings for Atara Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.


Atara Biotherapeutics logo

About Atara Biotherapeutics

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA2321 for acute myeloid leukemia; and ATA368 for human papillomavirus. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.11 out of 5 stars

Medical Sector

213th out of 842 stocks

Biological Products, Except Diagnostic Industry

36th out of 103 stocks

Analyst Opinion: 3.4Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Atara Biotherapeutics (NASDAQ:ATRA) Frequently Asked Questions

Is Atara Biotherapeutics a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Atara Biotherapeutics in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Atara Biotherapeutics stock.
View analyst ratings for Atara Biotherapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Atara Biotherapeutics?

Wall Street analysts have given Atara Biotherapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Atara Biotherapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Atara Biotherapeutics' next earnings date?

Atara Biotherapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Atara Biotherapeutics
.

How were Atara Biotherapeutics' earnings last quarter?

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) announced its quarterly earnings results on Monday, May, 3rd. The biotechnology company reported ($0.86) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.92) by $0.06. The biotechnology company earned $3.55 million during the quarter, compared to the consensus estimate of $7.19 million.
View Atara Biotherapeutics' earnings history
.

How has Atara Biotherapeutics' stock price been impacted by COVID-19?

Atara Biotherapeutics' stock was trading at $9.96 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ATRA stock has increased by 28.0% and is now trading at $12.75.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ATRA?

8 equities research analysts have issued 12 month price objectives for Atara Biotherapeutics' stock. Their forecasts range from $27.00 to $78.00. On average, they expect Atara Biotherapeutics' stock price to reach $38.00 in the next twelve months. This suggests a possible upside of 198.0% from the stock's current price.
View analysts' price targets for Atara Biotherapeutics
or view top-rated stocks among Wall Street analysts.

Who are Atara Biotherapeutics' key executives?

Atara Biotherapeutics' management team includes the following people:

What is Pascal Touchon's approval rating as Atara Biotherapeutics' CEO?

6 employees have rated Atara Biotherapeutics CEO Pascal Touchon on Glassdoor.com. Pascal Touchon has an approval rating of 60% among Atara Biotherapeutics' employees. This puts Pascal Touchon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Atara Biotherapeutics' key competitors?

What other stocks do shareholders of Atara Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Atara Biotherapeutics investors own include CRISPR Therapeutics (CRSP), AbbVie (ABBV), Exelixis (EXEL), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), OPKO Health (OPK), Gilead Sciences (GILD), Micron Technology (MU) and Pfizer (PFE).

What is Atara Biotherapeutics' stock symbol?

Atara Biotherapeutics trades on the NASDAQ under the ticker symbol "ATRA."

Who are Atara Biotherapeutics' major shareholders?

Atara Biotherapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include NEXT Financial Group Inc (0.01%). Company insiders that own Atara Biotherapeutics stock include Amar Murugan, Jakob Dupont, Joe Newell, Kristin Yarema, Pascal Touchon, Thomas Peterffy and Utpal Koppikar.
View institutional ownership trends for Atara Biotherapeutics
.

Which institutional investors are buying Atara Biotherapeutics stock?

ATRA stock was purchased by a variety of institutional investors in the last quarter, including NEXT Financial Group Inc.
View insider buying and selling activity for Atara Biotherapeutics
or or view top insider-buying stocks.

How do I buy shares of Atara Biotherapeutics?

Shares of ATRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Atara Biotherapeutics' stock price today?

One share of ATRA stock can currently be purchased for approximately $12.75.

How much money does Atara Biotherapeutics make?

Atara Biotherapeutics has a market capitalization of $1.07 billion. The biotechnology company earns $-306,620,000.00 in net income (profit) each year or ($4.15) on an earnings per share basis.

How many employees does Atara Biotherapeutics have?

Atara Biotherapeutics employs 480 workers across the globe.

What is Atara Biotherapeutics' official website?

The official website for Atara Biotherapeutics is www.atarabio.com.

Where are Atara Biotherapeutics' headquarters?

Atara Biotherapeutics is headquartered at 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Atara Biotherapeutics?

Atara Biotherapeutics' mailing address is 611 GATEWAY BLVD SUITE 900, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-278-8930.


This page was last updated on 7/31/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.